Table 2

Characteristics of included trials

TrialIntervention(s) and controlAge, years*Proportion of womenSymptom duration, yearsBaseline pain†Baseline function‡*
Paavola et al 13 ASAD (n=59)50.5 (7.3)71% (42/59)1.5 (1.2)7.12 (2.36)32.2 (28.2 to 36.2)
DA (n=63)50.8 (7.6)73% (46/63)1.5 (1.6)7.23 (2.17)31.7 (28.2 to 35.2)
ET (71)50.4 (6.6)66% (47/71)1.9 (1.9)7.24 (2.08)35.2 (31.4 to 39.0)
Beard et al 12 ASAD (n=106)52.9 (10.3)51% (54/106)6.0 (1.9)39.4 (13.9)
DA (n=103)53.7 (10.5)50% (52/103)5.8 (2.0)43.1 (15.5)
WaS (n=104)53.2 (10.2)50% (52/104)6.6 (1.7)38.3 (14.2)
Farfaras et al 25 ASAD (n=29)56 (11.3)
OSAD (n=24)48 (15.7)
ET (n=34)56 (13.1)
Ketola et al 35 ASAD (n=70)46.456% (41/70)2.5 (0.25–17)6.422.0
ET (n=70)47.867% (47/70)2.6 (0.25–20)6.517.5
Henkus et al 34 ASAD (n=30)50.047% (14/30)7.957
BT (n=26)43.065% (17/26)6.856
Taverna et al 42 ASAD (n=30)52.0 (7)57% (17/30)8.2 (0.8)54 (4)
MT (n=30)53.0 (7)70% (21/30)8.4 (0.9)51 (4)
Haahr et al 33 ASAD (n=41)44.371% (29/41)6.56 (5.78 to 7.33)33.7 (29.2 to 38.2)
ET (n=43)44.567% (29/43)7.22 (6.56 to 7.78)34.7 (30.4 to 39.0)
Peters and Kohn41 SAD (n=32)5644% (14/32)54
CT (n=40)5930% (12/40)59
Brox et al 30 ASAD (n=45)48.036% (16/45)7.25 (1.9)63.4 (10.8)
ET (n=50)47.056% (28/50)6.89 (2.3)66.3 (8.8)
Laser (n=30)48.050% (15/30)6.96 (2.5)64.7 (10.6)
  • Values presented as mean (SD) for age, mean (SD, minimum–maximum) for symptom duration, mean (SD, 95% CI) for baseline pain and mean (SD, 95% CI) for baseline function.

  • *Medians reported by Peters and Kohn.41

  • †Measures were transformed to a 0–10 scale, with a higher score indicating less pain.

  • ‡Measures were transformed to a 0–100 scale, with a higher score indicating superior function.

  • ASAD, arthroscopic subacromial decompression surgery; BT, bursectomy; CT, conservative therapy including ET; DA, diagnostic arthroscopy; ET, exercise therapy; MT, microtenotomy; OSAD, open subacromial decompression surgery; SAD, subacromial decompression surgery; WaS, wait and see.